How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Pharmaceutical Dissolution Testing Services Market
- By Service Type: Method Development and Validation, Routine Dissolution Testing, Stability Testing, Comparative Dissolution Testing, Regulatory Support Services
- By Dosage Form: Tablets, Capsules, Oral Suspensions, Transdermal Patches, Injectables
- By End User: Pharmaceutical Companies, Contract Research Organizations (CROs), Biotechnology Firms, Academic and Research Institutes, Regulatory Agencies
- By Technology Used: USP Apparatus 1 (Basket), USP Apparatus 2 (Paddle), USP Apparatus 3 (Reciprocating Cylinder), USP Apparatus 4 (Flow-Through Cell), UV-Visible Spectrophotometry
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Method Development and Validation leads By Service Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Pharmaceutical Dissolution Testing Services Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Service Type 5
Dosage Form 5
End User 5
Technology Used 5
Companies profiled
Eurofins Scientific
SGS SA
Intertek Group plc
Charles River Laboratories International Inc.
Pace Analytical Services
LLC
Covance Inc. (Labcorp Drug Development)
WuXi AppTec Co. Ltd.
ICON plc
Pharmaron
Toxikon Corporation
Frontage Laboratories Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Eurofins Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →SGS SA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Intertek Group plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Charles River Laboratories International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Pace Analytical Services
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →LLC
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Covance Inc. (Labcorp Drug Development)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →WuXi AppTec Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →ICON plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Pharmaron
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Toxikon Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Frontage Laboratories Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →BioDuro
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →QPS Holdings
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Catalent Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Almac Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,516M by 2033 · 5.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Method Development and Validation36.5
- Routine Dissolution Testing9.7
- Stability Testing12.7
- Comparative Dissolution Testing22.0
- Regulatory Support Services19.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$778.5M → $1,148M · 5.0%
Europe$542.6M → $821.8M · 5.3%
Asia Pacific$495.4M → $743.5M · 5.2%
Latin America$306.7M → $508.6M · 6.5%
Middle East and Africa$235.9M → $352.5M · 5.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.072026
5.082027
5.092028
5.112029
5.122030
5.132031
5.142032
5.142033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Eurofins Scientific19.9
- SGS SA20.6
- Intertek Group plc5.6
- Charles River Laboratories International Inc.5.2
- Pace Analytical Services8.3
- LLC12.3
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Service Type31.4%
Dosage Form19.2%
End User13.9%
Technology Used35.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.1
- Europe23.0
- Asia Pacific20.8
- Latin America14.2
- Middle East and Africa9.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Eurofins Scientific | 74 | 75 | 82 | 75 | 83 | 84 | 79 |
| SGS SA | 88 | 93 | 88 | 77 | 76 | 78 | 83 |
| Intertek Group plc | 63 | 87 | 87 | 72 | 63 | 73 | 74 |
| Charles River Laboratories International Inc. | 69 | 80 | 67 | 71 | 79 | 71 | 73 |
| Pace Analytical Services | 69 | 58 | 68 | 61 | 67 | 60 | 64 |
| LLC | 62 | 68 | 58 | 70 | 64 | 65 | 65 |
| Covance Inc. (Labcorp Drug Development) | 42 | 52 | 61 | 45 | 47 | 50 | 50 |
| WuXi AppTec Co. Ltd. | 59 | 60 | 38 | 57 | 44 | 44 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Eurofins Scientific
- SGS SA
- Intertek Group plc
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Eurofins Scientific | ✓ | − | ◐ | ◐ | ◐ | ◐ |
| SGS SA | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Intertek Group plc | ◐ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Charles River Laboratories International Inc. | ◐ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Pace Analytical Services | ◐ | ◐ | ◐ | ◐ | ✓ | ◐ |
| LLC | ◐ | − | ◐ | ✓ | − | − |
| Covance Inc. (Labcorp Drug Development) | − | ◐ | ◐ | − | − | − |
| WuXi AppTec Co. Ltd. | ◐ | − | ◐ | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1SGS SA83
2Eurofins Scientific79
3Intertek Group plc74
4Charles River Laboratories International Inc.73
5LLC65
6Pace Analytical Services64
7Covance Inc. (Labcorp Drug Development)50
8WuXi AppTec Co. Ltd.50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Eurofins ScientificSGS SA
Challenger2
Strong scale, closing on the leaders.
Intertek Group plcCharles River Laboratories International Inc.
Contender2
Focused players with pockets of strength.
Pace Analytical ServicesLLC
Niche2
Specialists in a single segment or region.
Covance Inc. (Labcorp Drug Development)WuXi AppTec Co. Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Service Type in North America, then scale across Pharmaceutical Dissolution Testing Services Market — a $601M beachhead inside a $9.83B market.
Beachhead (SOM)$601Mobtainable near-term
Serviceable (SAM)$3.49Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Method Development and Validation
Best fit — highest urgency & budget in Service Type.
Economic buyer79 fit
Routine Dissolution Testing
Strong fit — clear ROI and a fast path to value.
End user69 fit
Stability Testing
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Service Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Dosage Form & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Service Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Pharmaceutical Dissolution Testing Services Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified22%
Evaluation14%
Closed-won7%
$13.1KCAC
$51KLTV
3.9:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Pharmaceutical Dissolution Testing Services Market is a resilient opportunity — $1.08B by 2033, compounding at 4.8%.
TAM · 2025$737Mtoday
TAM · 2033$1.08Bforecast
CAGR4.8%2027–2033
Cumulative$8.08Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.08BTotal addressable market
SAM$372MServiceable available market
SOM$63MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.8% CAGR
Demand compounds through 2033, outpacing GDP across Service Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Service Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.08BLarge & growingTAM by 2033 at 4.8% CAGR
$372MServiceable nowreachable with today’s model
$63MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$840MBear3.2% CAGR
$1.08BBase4.8% CAGR
$1.38BBull6.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Dosage Form optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Pharmaceutical Dissolution Testing Services Market — a $8.29B market by 2033. Plan: grow share from 10.1% to 18.6%.
Market size · 2033$8.29Btotal addressable
Market CAGR6.2%2027–2033
Target share18.6%from 10.1% today
Revenue ambition$1.54Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.1% | 18.6% | On track |
| Revenue | $898M | $1.54B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 34.6% | 40.1% | On track |
| Customer retention | 84.2% | 95.7% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Service Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Dosage Form capability
A defensible second engine — invest in Dosage Form to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Service Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Dosage Form
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $225M capacity & capability investment
- Greenlight bolt-on M&A in Dosage Form
- Authorise North America expansion plan
- Fund R&D program for Service Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Pharmaceutical Dissolution Testing Services Market conversation — a $6.09B market you can size, segment and defend in minutes.
Market size · 2033$6.09Btotal opportunity
Growth4.5%CAGR to 2033
Addressable buyers1,002+accounts in scope
Typical ROI6.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Service Type
Goal Grow share in Service Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.3×return on cost, year one
< 3 mopayback period
$67K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Eurofins ScientificSGS SAIntertek Group plcCharles River Laboratories International Inc.Pace Analytical ServicesLLCCovance Inc. (Labcorp Drug Development)WuXi AppTec Co. Ltd.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Pharmaceutical Dissolution Testing Services Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Pharmaceutical Dissolution Testing Services Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Pharmaceutical Dissolution Testing Equipment Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportPharmaceutical Dipropylene Glycol Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportPharmaceutical Diaphragm Valves Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportPharmaceutical Development Preclinical CRO Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportPharmaceutical Desiccant Dehumidifier Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportPharmaceutical Desiccant Bag Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportPharmaceutical Deduster Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportPharmaceutical Decontamination Station Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportPharmaceutical Data Analysis Platform Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportPharmaceutical CXO Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportPharmaceutical CRM Software Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportPharmaceutical CRDMO Service Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.